Saphnelo approved in the US for moderate to severe systemic lupus erythematosus – AstraZeneca
AstraZeneca’s Saphnelo (anifrolumab-fnia) has been approved in the US for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy…. read more.
